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Induced stem cells as a novel multiple sclerosis therapy
Chong Xie1, Yan-qun Liu1, Yang-tai Guan1,*, and Guang-Xian Zhang2,*
1Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, 
China
2Department of Neurology, Thomas Jefferson University, Philadelphia, USA
Abstract
Stem cell replacement is providing hope for many degenerative diseases that lack effective 
therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of 
the central nervous system. Transplantation of neural stem cells or mesenchymal stem cells is a 
potential therapy for MS thanks to their capacity for cell repopulation as well as for their 
immunomodulatory and neurotrophic properties. Induced pluripotent stem cell (iPSC), an 
emerging cell source in regenerative medicine, is also being tested for the treatment of MS. 
Remarkable improvement in mobility and robust remyelination have been observed after 
transplantation of iPSC-derived neural cells into demyelinated models. Direct reprogramming of 
somatic cells into induced neural cells, such as induced neural stem cells (iNSCs) and induced 
oligodendrocyte progenitor cells (iOPCs), without passing through the pluripotency stage, is an 
alternative for transplantation that has been proved effective in the congenital hypomyelination 
model. iPSC technology is rapidly progressing as efforts are being made to increase the efficiency 
of iPSC therapy and reduce its potential side effects. In this review, we discuss the recent advances 
in application of stem cells, with particular focus on induced stem/progenitor cells (iPSCs, iNSC, 
iOPCs), which are promising in the treatment of MS.
Keywords
Multiple sclerosis; experimental autoimmune encephalomyelitis; neural stem cells; mesenchymal 
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1. Introduction
Multiple sclerosis (MS) is a common neurological disorder that targets white matter in the 
central nervous system (CNS), i.e., brain and spinal cord [1, 2]. MS remains one of the 
major causes of disability in young adults. Globally, the median estimated prevalence of MS 
is 30 per 100,000 and the median estimated incidence of MS is 2.5 per 100,000, with rates 
varying widely in different regions [3]. While the exact etiology is unknown, an aberrant 
immune response against CNS antigens, especially the activation of T helper cells, is 
thought to play a critical role in this disease [4]. MS is characterized by a cascade of 
pathological events ranging from inflammatory cell infiltration, demyelination in multiple 
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areas of the CNS, axonal degeneration, and neuron and oligodendrocyte loss [5]. The 
diagnosis of MS is based on clinical dysfunction and radiological abnormalities distributed 
throughout the CNS. Current therapeutic methods include relapse treatment, disease-
modifying treatment and treatment of symptoms [6–8]. Drugs such as interferon-β, 
fingolimod and natalizumab can slow disease progression and reduce relapse risk, but they 
cannot rectify the imbalanced immune response or repair demyelinated axons and impaired 
neural cells [9–15].
Because of their self-renewal and differentiation ability, stem cells have been recently 
proposed as a promising therapy for various degenerative disorders, including MS. Neural 
stem cells (NSCs) and mesenchymal stem cells (MSCs) are the most common stem cell 
types used in the treatment of MS. Studies have demonstrated that injection of NSCs or 
MSCs can alleviate neurological dysfunction and promote remyelination in experimental 
autoimmune encephalomyelitis (EAE), a widely used animal model of MS [16, 17]. It has 
been shown that the therapeutic effects of NSCs and MSCs are due to their neural cell 
repopulation and immunomodulatory properties, which make stem cell therapy more 
effective than current drugs. Not only can they halt the inflammatory demyelinating process 
in CNS, but they also differentiate into neurons and oligodendrocytes, the myelinating cells 
in CNS, to repair damaged tissues.
Eight years ago, a method of preparing another kind of stem cells, induced pluripotent stem 
cells (iPSCs), was developed by Yamanaka et al. [18]. Mouse somatic cells were 
reprogrammed into iPSCs by the introduction of four reprogramming factors. Soon 
afterward, iPSCs were also successfully generated from cells of MS patients [19, 20]. 
Amelioration of disability and myelin regeneration were observed after transplantation of 
iPSCs–derived NSCs and oligodendrocyte progenitor cell (OPCs) into EAE mice and other 
demyelinated animal models [21, 22]. Compared with other stem cells, iPSCs have the great 
advantage of being obtained from the patient’s somatic cells, thus avoiding both the risk of 
transplant rejection and ethical concerns. It is expected that iPSCs derived from MS patients 
will differentiate into neural lineages and tissues in vitro for disease modeling, 
pathomechanism exploration, drug testing and will then be transplanted into the patient to 
repair demyelinated lesions. A significant effort is being made to achieve that goal. Here we 
discuss the recent advances in stem cell therapy for MS, focusing on iPSC-based stem cell 
therapy.
2. Application of NSCs and MSCs in EAE
Before the development of iPSCs, other types of stem cells, NSCs and MSCs in particular, 
were studied in EAE mice [23, 24]. Convincing results have been observed and mechanisms 
underlying their effects have been studied, providing a strong basis for the potential use of 
iPSCs in demyelinating diseases. We will therefore first discuss recent progress in the 
application of NSCs/MSCs in EAE.
2.1. NSCs and EAE
NSCs are multipotent cells that can be obtained from multiple tissues, including embryo, 
bone marrow, fetal and adult nervous systems [25]. When NSCs were injected 
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intraventricularly into Lewis EAE rats to test their potential effects on the acute phase of 
MS, these cells attenuated the clinical severity of EAE and CNS inflammation [26, 27]. 
Further, NSCs were also injected both intravenously (i.v.) and intracerebroventricularly 
(i.c.v.) into myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide-induced EAE mice, 
and these cells were located exclusively in the lesioned areas of the CNS, where they 
effectively promoted remyelination and functional recovery [28].
In attempting to improve NSC transplantation, its therapeutic mechanism has been 
extensively investigated. NSC transplantation was originally viewed as a means of cell 
replacement based on their capacity to differentiate into myelin-forming cells and neurons 
[28]. In addition, a paracrine mechanism might also be involved in the beneficial effects of 
NSCs, as, for example, injected NSCs induced an upregulation of growth factors such as 
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and promoted 
proliferation and differentiation of endogenous OPCs [28]. Moreover, transplanted NSCs 
might promote blood-brain barrier (BBB) integrity and attenuate CNS inflammatory 
responses, e.g., decreased expression of intercellular adhesion molecule and leukocyte-
activating factor, inhibited lymphocyte proliferation and CNS infiltration [29, 30]. NSCs also 
induced apoptosis of infiltrating CD4+ T cells and increased the percentage of regulatory T 
cells, thus protecting neural tissues from inflammatory damage and reducing neurological 
disability [29].
Various modified methods have been tested to enhance the efficacy of NSC transplantation. 
For example, a great improvement in functional recovery was achieved by pre-treating 
MOG-induced EAE mice with osthole, a natural coumarin with a broad spectrum of 
pharmacological activities, including anti-inflammation, immunomodulation, and 
neuroprotection [31]. Similar results were also obtained by transfecting NSCs with IL-10, a 
potent immunomodulatory cytokine [32], and Neurotrophin 3, a neurotrophic factor that 
promotes neuron and oligodendrocyte development and survival [33]. Using in vivo MRI 
tracking analysis, studies have demonstrated that inflammatory signals in the CNS, such as 
increased concentrations of chemokines, attracted transplanted cells into the demyelinated 
areas [34, 35]. Thus, transfection of NSCs with a chemokine receptor, CCR-5, significantly 
enhanced the number of transplanted NSCs and their speed in reaching demyelinated foci, 
resulting in improvement of neurological function [36]. Moreover, after transplanting NSCs 
with Olig2, a greater number of NSCs differentiated into OPCs, making the therapy more 
effective [37].
NSC transplantation has proved to be a promising approach for different EAE models. With 
the development of iPSC technology, generation of induced NSCs (iNSCs) from human and 
mouse somatic cells by directly reprogramming with a single transcription factor (TF), or a 
set of them, is providing new avenues for MS treatment, which will be discussed in 4.1.
2.2. MSCs and EAE
MSCs, another type of multipotent cells, have been found in virtually all tissues, including 
bone marrow (BM) and adipose tissue [23]. Two early studies demonstrated that 
transplanted BM-MSCs alleviated pathological features and improved functional recovery in 
both myelin proteolipid protein (PLP)-induced and MOG-induced EAE mice [38, 39]; more 
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recently, other studies showed that MSCs from BM and adipose tissue reduced infiltration of 
inflammatory cells into the CNS [40–42]. Moreover, MSCs from MOG-induced EAE mice 
had similar biological properties as MSCs from healthy donors, making possible the use of 
autologous MSCs from MS patients [43]. To improve the effects of MSCs therapy, different 
modified methods were tested. For instance, inhibition of autophagy in MSCs by 
knockdown of Becn1 significantly improved their therapeutic effects [44].
The therapeutic mechanism of MSCs in alleviating the clinical course of EAE is still 
controversial. It was found that the majority of transplanted MSCs migrated to lymphoid 
organs and induced a T-cell unresponsive state in MOG-induced EAE mice [38]. By using 
enhanced green fluorescent protein (eGFP) to track MSCs, Gerdoni et al. did not find any 
GFP+ neural cells within the brain parenchyma [17], indicating that MSCs might exert their 
beneficial effects by modulating the immune system, but not by neural cell repopulation [45, 
46]. Nevertheless, MSCs also promoted endogenous neural generation though BDNF 
secretion [39]. Thus, MSCs exerted therapeutic effects on EAE not only through their 
immunomodulation function, but also their neurotrophic capacity.
3. Application of iPSC-based cell therapy
The breakthrough innovation of iPSCs has sparked an enormous global effort to carry out 
disease modeling, drug screening and regenerative therapy. The reprogrammed cells have 
similar morphologies to embryonic stem cells (ESCs) and can differentiate into cell types 
representing all three embryonic germ layers [18]. Subsequent successful attempts to 
generate human iPSCs from both healthy and diseased individuals have brought us several 
steps closer to clinical application [47–49]. This technology makes it possible for pluripotent 
cells reprogrammed from the MS patient’s somatic cells to differentiate in vitro into the 
desired cell lineages or tissues for both pathophysiological research and in vivo cell-based 
treatment. The therapeutic effects of these cells have been tested in EAE and other 
demyelinated model systems, as summarized in Table 1.
3.1. IPSCs can differentiate into oligodendrocyte lineage in vitro
Successful differentiation of iPSCs into oligodendrocyte lineage is fundamental for the 
treatment of MS. In 2010, Tokumoto compared the differentiating ability of mouse iPSCs 
with ESCs. After induction, OPC marker A2B5 positive cells and oligodendrocyte-specific 
cell surface marker O4 positive cells were observed in both iPSC- and ESC-derived cells 
[50]. Human iPSCs were first induced to differentiate to oligodendrocytes in 2011 [51]. 
Fibroblast-derived iPSCs from healthy adults were treated with epidermal growth factor-
dependent differentiation protocol and eventually differentiated to O4+ oligodendrocytes. 
However, the efficiency was low (less than 0.01%). Fibroblasts from relapsing-remitting 
multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) patients were 
also reprogrammed into iPSCs, and these MS-iPSCs successfully differentiated into mature 
neurons, astrocytes and oligodendrocytes with normal karyotypes. The MS-iPSC derived 
neurons were electrophysiologically functional, and the oligodendrocytes displayed positive 
staining for myelin basic protein (MBP) and O4. Generation of neural cells from MS-iPSCs 
in vitro was an important step toward achieving individualized treatment [19].
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3.2. Effects of iPSC-derived NSCs on EAE
Given the therapeutic effects of subventricular zone- and BM-derived NSCs on EAE [28, 
52], it has been proposed that iPSC-derived NSCs have similar effects. To test this, Laterza 
et al. generated NSCs from mouse iPSCs and transplanted them into MOG-induced EAE 
mice intrathecally. The NSC-treated EAE mice showed clinical amelioration, with reduced 
demyelinated areas and axonal damage in the spinal cord. However, the majority of 
transplanted NSCs did not differentiate into oligodendrocyte lineages in vivo, indicating that 
they did not participate in remyelination directly. Nevertheless, iPSC-derived NSCs 
promoted the survival and differentiation of endogenous myelin-forming cells by secreting a 
specific neurotrophin: leukaemia inhibitory factor. The trophic effect mediated by NSCs also 
improved BBB integrity, thus limiting the CNS-confined inflammation [21]. Given that 
myelin damage is often caused by CNS inflammation, exerting neuroprotective and 
neurotrophic effect within an inflammatory environment makes iPSC-NSCs a promising cell 
source for treating MS.
3.3. Effects of iPSC-derived OPCs on chemically-induced demyelinated and congenital 
hypomyelination models
In addition to iPSC-derived NSCs, another common cell source for transplantation was 
iPSC-derived OPCs. The myelin-forming capacity of iPSC-derived OPCs was examined in 
vivo by injecting them into the demyelinated corpus callosum of cuprizone-fed mice; the 
implanted OPCs developed into mature MBP+ oligodendrocytes that contributed to the 
remyelination of the corpus callosum axons [53]. OPCs derived from human iPSCs were 
also transplanted into the lysolecithin-induced demyelinated rat optic chiasm [54]. Obvious 
remyelination was revealed by luxol fast blue myelin-specific staining after transplantation. 
The visual evoked potential recording also reflected functional improvement. The 
transplanted cells differentiated into mature oligodendrocytes and integrated within the 
chiasm, contributing to remyelination and functional recovery.
Human iPSC-derived OPCs were also tested in shiverer mouse, a genetic model of 
congenital hypomyelination [22]. Mice transplanted with iPSC-OPCs exhibited markedly 
improved survival, with reduced mortality over a 9-month period of observation. Robust 
donor-derived myelination, with a higher proportion of ensheathed axons in recipient brains, 
was revealed by confocal images [22]. MS-iPSC-derived OPCs were also injected into 
shiverer mice to evaluate their myelinogenic ability. After 16 weeks, human MBP+ 
oligodendrocytes were found diffusely throughout the engrafted corpus callosum, and about 
30% of host mouse axons were ensheathed [20]. Together, these results provided direct 
evidence for the myelinogenic effect of iPSC-derived OPCs in vivo.
3.4. Modifications to improve the generation and migration of iPSC-derived OPCs
Although iPSC-derived OPCs can differentiate into mature oligodendrocytes and form 
myelin in vivo, it is difficult to acquire large numbers of autologous OPCs [55]. Modifying 
the protocols to generate sufficient iPSC-OPCs in a relatively short time is crucial. In an 
attempt to do so, Douvaras et al. induced OPCs from iPSCs by dual inhibition of SMAD 
signaling in adherent cultures and addition of retinoic acid and/or sonic hedgehog; 44%-70% 
OPCs were obtained after 75 days of differentiation, compared with the minimum of 120 
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days previously required [20]. Furthermore, it was found that the differentiation rate of 
iPSCs-derived OPCs into O4+ oligodendrocytes was increased by overexpression of p27, 
and the differentiation efficiency was enhanced over eightfold compared with the control 
experiments [56].
While iPSC-derived OPCs have the ability to generate and restore the myelin sheath, they 
have limited capacity to migrate along the axons [53]. To increase the migratory capacity of 
these cells, overexpression of sialyltransferase X (STX) was induced in iPSC-derived OPCs 
via lentiviral transduction, after which transfected cells were injected into the cuprizone-fed 
demyelinated mice to examine their migratory and myelinogenic behavior. At 3 weeks after 
implantation, STX-transfected OPCs survived and repopulated the corpus callosum along its 
entire width on the unilateral side of the injection. A significant increase in migration along 
the axons was revealed compared with control OPCs [57].
4. Direct transdifferentiation of somatic cells to NSCs and OPCs
After the successful reprogramming of somatic cells to iPSCs, a more direct lineage 
conversion of fibroblasts to functional neurons by defined factors was achieved in 2010 [58]. 
This novel approach made it possible for a fully differentiated cell to be transformed into 
another specialized cell type without passing through the pluripotency stage. Subsequently, 
strategies were developed for the generation of other induced neural lineage cells using 
specific sets of TFs in optimal culture conditions [59, 60].
4.1. Induced neural stem cells (iNSCs)
In 2011, Kim et al. first showed that four Yamanaka reprogramming factors in combination 
with NSC-permissive culture condition directly transformed fibroblasts to iNSCs [61]; these 
iNSCs differentiated to neurons and astrocytes, but self-renewed for only 3–5 passages. 
Thier et al. also generated iNSCs that could be expanded for more than 50 passages by 
constitutively inducing Sox2, Klf4 and c-Myc while strictly limiting Oct4 activity [62]. The 
iNSCs not only had a similar genome-wide transcriptional profile compared to brain-derived 
NSCs, but they could also differentiate into neurons, astrocytes, and oligodendrocytes. 
Tripotent, self-renewing iNSCs were also induced using a combination of TFs: Brn4/Pou3f4, 
Sox2, Klf4, c-Myc, plus E47/Tcf3 [63]. Furthermore, Ring et al. reported the generation of 
iNSCs by direct reprogramming with a single TF: Sox2. The implanted Sox2-induced iNSCs 
survived and was integrated into mouse brains and did not generate tumors [64].
The effects of iNSCs were also examined in a congenital hypomyelination model. Lujan et 
al. injected iNSCs that were eGFP positive into the neonatal brain of shiverer mouse [65]. 
Ten weeks after transplantation, eGFP+ cells and MBP+ myelin sheaths were observed in 
white-matter tracts of the cerebellum. This result indicates that iNSCs differentiated into 
myelinating oligodendrocytes and restored myelin sheaths.
4.2. Induced oligodendrocyte progenitor cells (iOPCs)
Najm et al. [66] found that forced expression of sets of 8 or 3 defined TFs could directly 
reprogram mouse fibroblasts into myelinogenic iOPCs, obviating the use of iPSCs. The 8 
TFs (Olig1, Olig2, Nkx2.2, Nkx6.2, Sox10, ST18, Gm98 and Myt1) or 3 TFs (Nkx6.2, 
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Sox10, Olig2)-induced mouse fibroblast globally expressed OPC genes and could 
differentiate into cells with a typical morphology of oligodendrocytes. The iOPCs generated 
characteristically MBP+ myelin sheaths after being transplanted into organotypic slice 
cultures, which provided a complex 3D tissue representative of the CNS. Compact myelin 
sheaths around dorsal column axons were also restored. Furthermore, the authors found that 
the efficiency of generating functional iOPCs was enhanced by increasing the viral titer of 
the TFs [66].
Consistent with Najm’s study, Yang et al. [67] also generated iOPCs from mouse and rat 
fibroblasts using 3 TFs (Sox10, Olig2 and Zfp536). These iOPCs exhibited properties of 
bona fide OPCs; they gave rise to MBP+ cells that showed mature oligodendrocytic 
morphologies and myelinated the axons of dorsal root ganglion neurons in vitro. When 
iOPCs were injected into shiverer mouse brains, small scattered groups of MBP+ cells 
forming tube-like structures that surrounded axons were detected at all injection sites of 
brain. The myelin formation of transplanted iOPCs was also confirmed by ultrastructural 
analysis. These results strongly indicated the myelinogenic capacity of iOPCs.
Although iNSCs and iOPCs have not been tested in EAE mice, they may be more 
advantageous than other types of stem cells. First, iNSCs and iOPCs have shown their 
myelinogenic ability in vitro and in vivo, which is advantageous over MSCs. Second, a 
relatively simpler generation protocol makes their use less effort- and cost-consuming than 
iPSCs. Last but not least, iNSCs and iOPCs are autologous cells, making them promising 
candidates for individualized cell treatment compared to those derived from ES cells or stem 
cells of umbilical cord blood. Certainly, the therapeutic effects of iNSCs and iOPCs on 
EAE/MS need to be evaluated by further studies.
5. Therapeutic mechanisms of stem cells
Although spontaneous recovery is observed in the early stage of MS, endogenous processes 
of repair and remyelination are typically incomplete and ultimately fail in the setting of 
recurrent episodes. Exogenous stem cell transplantation has therefore been advocated for 
regenerative medicine. Accumulated studies have shown the therapeutic effects of NSCs or 
MSCs on EAE. iPSC-based stem cells, including iPSCs-derived NSCs and OPCs, iNSCs, 
iOPCs, have also shown their potential in treatment of EAE/MS. The underlying 
mechanisms for the beneficial effects of stem cells may include: 1) as an exogenous source 
of neuron/oligodendrocyte repopulation; 2) immunomodulation, thus converting the CNS 
microenvironment from a hostile to a supportive one; and 3) neurotrophic effects, thus 
promoting endogenous neuron/oligodendrocyte differentiation and regeneration.
In the acute phase of EAE, the immunoregulatory property of stem cells protects tissue from 
attacks of abnormal inflammation; in the chronic phase, stem cells secrete neurotrophic 
factors to promote endogenous remyelination. Furthermore, NSCs also produce matrix 
metallo proteinases that degrade extracellular matrix and cell surface molecules that impede 
axonal regeneration, thus enabling axons to extend through the glial scar [68]. Meanwhile, 
stem cells also provide exogenous neurons and oligodendrocytes to restore myelin and 
axons.
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6. Challenges confronting clinical application of iPSC-derived stem cells in 
MS
IPSCs are similar to ESCs in morphology and ability to proliferate and differentiate, which 
makes them a promising candidate for regenerative medicine. The fact that they are easily 
obtained from somatic cells makes their use free from ethical concerns. Furthermore, 
patient-derived iPSCs are immunologically privileged for transplantation, eliminating the 
need for lifelong immunosuppressive drugs. These advantages make iPSC-derived stem cells 
attractive for clinical application in MS treatment. However, many obstacles need to be 
surmounted before this can become a reality. These obstacles include the genomic instability 
of iPSCs, which is potentially tumorigenic. Some TFs, such as c-Myc, used to generate 
iPSCs are potent oncogenes [69]. In addition to these safety concerns, current methods for 
generating iPSCs are inefficient and time-consuming, and there remains a tremendous gap 
between generation of iPSC-derived stem cells for research and for therapeutic purposes [70, 
71].
In addition to the common challenges with iPSCs, MS adds three more challenges to the 
complex, in vivo microenvironment surrounding transplanted iPSC-derived stem cells in 
CNS foci: 1) persistent CNS inflammation, including BBB disruption, high numbers of 
infiltrating immune cells, and increased levels of proinflammatory cytokines, nitric oxide 
and other cytotoxic molecules, etc. [72, 73]; 2) loss of trophic support for both 
oligodendrocytes and neurons [74]; and 3) accumulation of neuroregeneration inhibitors, 
including myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein and Nogo A 
[75, 76]. The vicious cycle involving these mechanisms results in a hostile 
microenvironment, which not only leads to the failure of endogenous remyelination, but 
would also inhibit for the regenerating capacity of transplanted (exogenous) cells. 
Approaches to convert the hostile CNS microenvironment to a supportive one needs to be 
further studied for future MS therapy.
7. Conclusions
In this review we summarized the recent advances in application of iPSC-derived stem cells 
in treatment strategies for MS/EAE (summarized in Fig. 1). While NSCs and MSCs have 
long been tested as an effective MS/EAE therapy, the successful generation of iPSCs from 
somatic cells opens up a new era of stem cell therapy. The advantages of being easily 
obtained from the patient’s own tissue and being well tolerated make iPSC-derived stem 
cells, especially iNSCs and iOPCs, the most suitable candidates for individualized cell 
replacement therapy. After being examined in EAE and other demyelinated models, iPSC-
derived stem cells have shown great potential in the treatment of MS. Although there are still 
many problems to be solved before clinical application, we anticipate that, with the dramatic 
progress in the iPSC field, these challenges can be met, making iPSC-derived stem cell 
transplantation an autologous, safe and highly effective therapy for MS.
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Abbreviations
BBB blood-brain barrier
BDNF brain-derived neurotrophic factor
BM bone marrow
CNS central nervous system
EAE experimental autoimmune encephalomyelitis
eGFP enhanced green fluorescent protein
ESC embryonic stem cell
iNSC induced neural stem cell
iOPC induced oligodendrocyte progenitor cell
iPSC induced pluripotent stem cell
MBP myelin basic protein
MOG myelin oligodendrocyte glycoprotein
MS multiple sclerosis
MSC mesenchymal stem cell
NGF nerve growth factor
NSC neural stem cell
OPC oligodendrocyte progenitor cell
PLP proteolipid protein
PPMS primary progressive multiple sclerosis
RRMS relapsing remitting multiple sclerosis
STX sialyltransferase X
TF transcription factor
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Fig. 1. Application of induced stem cells in treatment of MS
iPSCs: induced pluripotent stem cells; NSCs: neural stem cells; OPCs: oligodendrocyte 
progenitor cells; iNSC: induced neural stem cell; iOPC: induced oligodendrocyte progenitor 
cell.
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